Prostate Cancer Screening 2nd Edition by Donna Ankerst, Catherine Tangen, Ian Thompson ISBN 1603272810 9781603272810
Original price was: $50.00.$35.00Current price is: $35.00.
Prostate Cancer Screening 2nd Edition by Donna Ankerst, Catherine Tangen, Ian Thompson – Ebook PDF Instant Download/Delivery: 1603272810, 9781603272810
Full download Prostate Cancer Screening 2nd edition after payment
Product details:
ISBN 10: 1603272810
ISBN 13: 9781603272810
Author: Donna Ankerst, Catherine Tangen, Ian Thompson
More than one in six men will develop prostate cancer in their lifetime. In recent years there has been an explosion of information regarding PSA screening and biomarkers for the disease. In Prostate Cancer Screening, Second Edition, the world’s leading experts on prostate cancer detection update the first edition with the latest findings. The book incorporates a series of thoughtful and cutting-edge works from the world’s experts in prostate cancer screening, ranging from the current status quo of prostate cancer screening across the globe to consensus on optimal utilization of the traditional PSA and DRE tests, to cutting-edge research in new biomarkers, biomeasures, and extended risk algorithms for prostate cancer. An additional chapter covers family-based linkage analysis as well as possible pitfalls in prostate cancer biomarker evaluation studies. Timely and authoritative, Prostate Cancer Screening, Second Edition, is an essential text for urologists, oncologists and family physicians, as well as researchers in the biomarker industry who seek methods to better develop and support markers and measures of prostate cancer.
Prostate Cancer Screening 2nd Table of contents:
I Trends in Prostate Cancer Screening
1 Overview of US Prostate Cancer Trends in the Era of PSA Screening
Ruth Etzioni, Roman Gulati, and Angela Mariotto
2 Trends in Prostate Cancer Screening: Overview of the UK
Richard J. Bryant and Freddie C. Hamdy
3 Trends in Prostate Cancer Screening: Canada
Robert K. Nam and Laurence H. Klotz
4 Trends in Prostate Cancer Screening — Overview of Europe
Sanjai K. Addla and Bob Djavan
II Prostate-Specific Antigen
5 Evolution of Prostate-Specific Antigen for Screening
Javier Hernandez and Edith Canby-Hagino
6 The Performance Characteristics of Prostate-Specific Antigen for ProstateCancer Screening
Ian M. Thompson and Donna P. Ankerst
7 The Performance of PSA for Predicting Prostate Cancer After a Prior NegativeProstate Biopsy
Catherine M. Tangen
8 Subfractions and Derivatives of Total Prostate-Specific Antigen in the EarlyDetection of Prostate
Alexander Haese and Alan W. Partin
9 PSA Velocity at Presentation as a Predictor of Prostate Cancer Aggressiveness
Jason A. Efstathiou and Anthony V. D’Amico
III Risk Assessment for ProstateCancer
10 Nomograms for Prostate Cancer
Shahrokh F. Shariat and Michael W. Kattan
11 Decision Aid Criteria and Artificial Neural Networks for Optimizing ProstateCancer Risk Predictio
Felix K.-H. Chun and Pierre I. Karakiewicz
12 Development of the Prostate Cancer Prevention Trial Prostate CancerRisk Calculator
Donna P. Ankerst and Ian M. Thompson
13 Integration of Risk Assessment in Prostate Cancer Screening
Kadee E Thompson, Amanda Reed, and Dipen J Parekh
14 Family History of Prostate Cancer During Rapidly Increasing Incidence
Kari Hemminki and Justo Lorenzo Bermejo
IV Recent Biomarkers for Prostate Cancer
15 PSA Isoforms: [-2]proPSA Significant Adjunct to Free PSA
Jeffrey E. Tam
16 PCA3
Jack Groskopf, Jack Schalken, and Harry Rittenhouse
17 Transcriptional Profiling of Prostate Cancer: Biomarker Identificationand Clinical Applications
Nigel Clegg and Peter S. Nelson
18 Biomarkers for Prostate Cancer Detection: Family-Based Linkage Analysisand Case–Control Associat
Joke Beuten and Teresa L Johnson-Pais
19 GSTP1 Hypermethylation for Prostate Cancer Detection
Rui Henrique and Carmen Jerónimo
20 EPCA and EPCA-2 as Potential Biomarkers for Prostate Cancer Detection
Eddy S. Leman and Robert H. Getzenberg
V Design and Methodologic Considerationsin Biomarker Studies
21 Toward a Robust System for Biomarker Triage and Validation — EDRNExperience
Ziding Feng, Jacob Kagan and Sudhir Srivastava
22 Statistical Evaluation of Markers and Risk Tools for Prostate CancerClassification and Prediction
Yingye Zheng and Donna P. Ankerst
23 Pitfalls in Prostate Cancer Biomarker Evaluation Studies
Donna P. Ankerst
VI Building upon Recently Completedand Ongoing Prospective Trials
24 Prostate-Specific Antigen and Its Role on the Prostate Cancer Prevention Trial
Catherine M. Tangen and Phyllis J. Goodman
25 The Selenium and Vitamin E Cancer Prevention Trial
Eric A. Klein
26 PLCO: A Randomized Controlled Screening Trial for Prostate, Lung, Colorectal,and Ovarian Cancer
Amanda Black, Robert L. Grubb III, and E. David Crawford
27 The European Randomized Study of Screening for Prostate Cancer (ERSPC)
Tineke Wolters and Fritz H. Schröder
People also search for Prostate Cancer Screening 2nd:
uspstf prostate cancer screening
prostate cancer screening guidelines
when to start prostate cancer screening
prostate cancer screening age
how is prostate cancer screening done
Tags: Donna Ankerst, Catherine Tangen, Ian Thompson, Prostate Cancer Screening